Project Details
Projekt
Site-specific inhibition of C5/C5a in pemphigoid diseases (B01)
Subject Area
Dermatology
Term
since 2022
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 454193335
Complement proteins C5 and C5a are key drivers of the effector phase of the pathogenesis of pemphigoid diseases (PD), but the systemic inhibition of C5/C5a may be associated with severe infections. To generate site-specific therapeutics, antibody fragments against PD autoantigens will be fused with those against C5/C5a, resulting in classical bispecific antibodies and hemibodies which only assemble a second functional antibody domain after binding to their targets. The therapeutic potential of these novel reagents will be evaluated in vitro, ex vivo, and in different mouse models of PDs.
DFG Programme
Collaborative Research Centres
Subproject of
SFB 1526:
Pathomechanisms of Antibody-mediated Autoimmunity (PANTAU): Insights from Pemphigoid Diseases
Applicant Institution
Universität zu Lübeck
Project Heads
Professor Dr. Ralf Joachim Ludwig, since 12/2022; Professor Dr. Matthias Peipp
